Investors / Canada / adMare BioInnovations
adMare BioInnovations
Venture capital · Canada · North America
adMare BioInnovations builds and scales Canadian life sciences companies, providing early-stage capital, scientific and drug development expertise, and lab and office facilities. It also runs talent and leadership development programs and manages a portfolio of life sciences companies.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechdrug developmenthealthcarecompany creation
Your fit with adMare BioInnovations
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsadMare BioInnovations lists 4 checked portfolio companies on its own site and is named in 4 funding rounds. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 50% of its companies are based in Canada. It invests most often alongside CTI Life Sciences Fund, Lumira Ventures and Seido Capital.
Counts come from funding rounds that name adMare BioInnovations, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 50% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 4 | 0 |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| CTI Life Sciences Fund | 3 |
| Lumira Ventures | 2 |
| Seido Capital | 2 |
| 3B Future Health Fund | 1 |
| Amplitude Ventures | 1 |
| Creative Destruction Lab | 1 |
| DeepWork Capital | 1 |
| Genesys Capital | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers4100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with CTI Life Sciences Fund
Compare adMare BioInnovations head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with adMare BioInnovations| Date | Company | Stage |
|---|---|---|
| 3 Nov 2026 | Series B | |
| 2 Nov 2026 | Series A | |
| 10 Feb 2026 | Series B | |
| 9 Jan 2026 | Series A |
Round details for adMare BioInnovations
Amounts, full round histories and every co-investor in adMare BioInnovations' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
4 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Domain Therapeutics develops breakthrough GPCR-targeting therapies for patients, especially in immuno-oncology and inflammation. | Healthcare & Biotech | Feb 2026Series B | Funding round | |
| The company designs ground-breaking therapies through precision-targeting of membrane receptors to treat demyelinating diseases | Healthcare & Biotech | Jan 2026Series A | Funding round | |
| Specific Biologics develops gene-editing therapies, including a genome editing platform called Dualase, for various diseases | Healthcare & Biotech | Nov 2026Series A | Funding round | |
| Thryv Therapeutics is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision medicines for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. | Healthcare & Biotech | Nov 2026Series B | Funding round |
About this data
site last read 5 Nov 2026- Site
- admarebio.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 9 Jan 2026
- Companies checked
- 4
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get adMare BioInnovations' profile as data
Pull adMare BioInnovations' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/admarebio.com
# also
GET /v1/firms/admarebio.com/portfolio
GET /v1/firms/admarebio.com/coinvestors
GET /v1/firms/admarebio.com/news